Guangji Pharmaceutical's first-half loss narrows to 57.9451 million yuan

Earnings
โดย 证券时报·CN·Read original
Summary · why it matters

Guangji Pharmaceutical released its 2026 half-year report on August 27. The company achieved operating revenue of 312 million yuan, up 9.71 percent year on year. Net loss attributable to shareholders was 57.9451 million yuan, compared with a loss of 75.5151 million yuan in the same period last year, narrowing the loss. During the reporting period, sales volume of the company's main product, vitamin B2, increased significantly compared with the same period last year.

Impact on stocks 1

Others▲ · 1 stocks
© 2026 MarketDXNews